XOFLUZA was as safe and well-tolerated as placebo in clinical trials 1*

XOFLUZA had a similar or lower adverse event rate than placebo across 2 clinical trials.

The safety and efficacy of XOFLUZA have not been established in pediatric patients under 12 years of age or weighing less than 40 kg.

*Based on combined Trial 1 and Trial 2 data, a total of 910 subjects received XOFLUZA: 834 (92%) were adults (aged ≥ 18 years) and 76 (8%) were adolescents (aged 12 to < 18 years). Of these, 710 subjects received XOFLUZA at the recommended dose.

The first and only 1-dose oral antiviral

XOFLUZA is just 1 dose—keeping your patients on track to be over and done with the flu. 1